CFR Pharmaceuticals Announces Further Extension To The Date For Fulfilment Or Waiver Of The Pre-Conditions To The Revised Scheme Consideration

Published: Jan 21, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SANTIAGO, Chile, Jan. 20, 2014 (GLOBE NEWSWIRE) -- Shareholders of CFR and Adcock Ingram are referred to the joint announcement ("Revised Scheme Consideration Announcement") released by Adcock Ingram and CFR on the Stock Exchange News Service of the JSE Limited on Friday, 13 December 2013 regarding, among others, CFR's intention to increase the total consideration to be discharged to holders of the Scheme Shares in terms of the Scheme from approximately US$1.22 billion in aggregate to approximately US$1.23 billion in aggregate (based on the fixed attributed value of ZAR2.334 per CFR Share) by virtue of the increase in the number of CFR Shares being offered pursuant to CFR's capital increase process in Chile.

Help employers find you! Check out all the jobs and post your resume.

Back to news